Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells

Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-02, Vol.104, p.85-90
Hauptverfasser:	Sesumi, Yuichi, Suda, Kenichi, Mizuuchi, Hiroshi, Kobayashi, Yoshihisa, Sato, Katsuaki, Chiba, Masato, Masaki, Shimoji, Tomizawa, Kenji, Takemoto, Toshiki, Mitsudomi, Tetsuya
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired resistance Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor - drug effects Cell Line, Tumor - metabolism Dasatinib Dasatinib - pharmacology Drug Resistance, Neoplasm Drug Therapy, Combination - methods Epithelial-mesenchymal transition Epithelial-Mesenchymal Transition - drug effects Epithelial-Mesenchymal Transition - genetics Erlotinib Hydrochloride Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Non-small cell lung cancer Protein Kinase Inhibitors - pharmacology Pulmonary/Respiratory Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Third- generation EGFR-TKI Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.12.012